AAV9 Gene Therapy in Type II GM1 Gangliosidosis — A Phase 1–2 Trial
New England Journal of Medicine · 26.03.2026 · 394 (12) · 1184-1194
DOI: 10.1056/nejmoa2510935 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift New England Journal of Medicine, erschienen am 26.03.2026. Verfasst von Connor J Lewis und 30 weiteren Autor:innen. Beteiligte Einrichtung: Office of the Clinical Director, National Human Genome Research Institute, Bethesda, MD. Hauptthemen laut MEDLINE: beta-Galactosidase, Gangliosidosis, GM1, Genetic Therapy, Genetic Vectors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHGRI NIH HHS, University of Massachusetts Medical School, NINDS NIH HHS.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Office of the Clinical Director, National Human Genome Research Institute, Bethesda, MD.
- Medical Genetics Branch, National Human Genome Research Institute, Bethesda, MD.
- Neurodevelopmental and Behavioral Phenotyping Service, National Institute of Mental Health, Bethesda, MD.
- Department of Diagnostic Radiology, National Institutes of Health Clinical Center, Bethesda, MD.
- Division of Diagnostic Imaging and Radiology, Children's National Hospital, Washington, DC.
- Department of Perioperative Medicine, National Institutes of Health Clinical Center, Bethesda, MD.
ORCID-Profile: Connor J Lewis, Meghan Blackwood, Kirsten Coleman, Terence R Flotte
Förderung
- NHGRI NIH HHS
- University of Massachusetts Medical School
- NINDS NIH HHS
- Auburn University
- National Tay-Sachs and Allied Diseases Association
- Washington University School of Medicine in St. Louis
- University of Florida
- NIMH NIH HHS
Zitieren
APA
Lewis, C. J., D'Souza, P., Johnston, J. M., Acosta, M. T., Farmer, C., Baker, E. H., Crowell, A., Mojica, Y., Ashraf, S., Joseph, L., Vézina, G., Quezado, Z., Yousef, M. H., Vardar, Z., Shazeeb, M. S., Corti, M., Blackwood, M., Coleman, K., Batista, R., …, & Tifft, C. J. (2026). AAV9 Gene Therapy in Type II GM1 Gangliosidosis — A Phase 1–2 Trial. New England Journal of Medicine, 394(12), 1184-1194. https://doi.org/10.1056/nejmoa2510935
Vancouver
Lewis CJ, D'Souza P, Johnston JM, Acosta MT, Farmer C, Baker EH, et al. AAV9 Gene Therapy in Type II GM1 Gangliosidosis — A Phase 1–2 Trial. New England Journal of Medicine. 2026;394(12):1184-1194. doi:10.1056/nejmoa2510935
BibTeX
@article{Lewis2026,
author = {Lewis, Connor J and D'Souza, Precilla and Johnston, Jean M and Acosta, Maria T and Farmer, Cristan and Baker, Eva H and Crowell, Anna and Mojica, Yoliann and Ashraf, Sumaiya and Joseph, Lisa and Vézina, Gilbert and Quezado, Zenaide and Yousef, Muhammad H and Vardar, Zeynep and Shazeeb, Mohammed Salman and Corti, Manuela and Blackwood, Meghan and Coleman, Kirsten and Batista, Rita and Thurm, Audrey and De Boever, Erika and Gahl, William A and Byrne, Barry J and Flotte, Terence R and Jiang, Xuntian and Gross, Amanda L and Keeler, Allison M and Gray-Edwards, Heather and Martin, Douglas R and Sena-Esteves, Miguel and Tifft, Cynthia J},
title = {AAV9 Gene Therapy in Type II GM1 Gangliosidosis — A Phase 1–2 Trial},
journal = {New England Journal of Medicine},
year = {2026},
volume = {394},
number = {12},
pages = {1184--1194},
doi = {10.1056/nejmoa2510935}
}
EUVIMED